text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며, 제66기 연결재무정보 및 재무정보는 주주총회 승인 전 재무제표로 향후 정기주주총회에서 재무제표 승인 관련 안건이 부결되거나 수정이 발생한 경우 정정보고서를 통해 그 내용 및 사유를 반영할 예정입니다.\n요약연결재무정보\n국제약품(주) 및 종속기업 \xa0\xa0\n(단위 : 원)\n구 분\n제66기\n제65기\n제64기\n[유동자산]\n55,119,200,302\n48,535,452,258\n48,197,308,387\n-현금및현금성자산\n10,589,867,418\n5,538,928,478\n7,866,062,183\n-매출채권\n20,429,244,439\n19,131,334,053\n20,652,657,728\n-재고자산\n21,243,101,813\n22,235,167,103\n16,540,406,112\n-기타유동자산\n2,856,986,632\n1,630,022,624\n3,138,182,364\n[비유동자산]\n108,140,282,905\xa0\n88,057,410,548\xa0\n91,585,738,297\n-유형자산\n98,482,998,265\xa0\n76,828,012,026\xa0\n80,044,733,529\n-무형자산\n919,291,953\xa0\n1,125,437,214\xa0\n1,333,272,730\n-투자부동산\n3,287,243,561\xa0\n3,444,971,576\xa0\n3,354,393,245\n-기타비유동자산\n5,450,749,126\xa0\n6,658,989,732\xa0\n6,853,338,793\n자산총계\n163,259,483,207\xa0\n136,592,862,806\xa0\n139,783,046,684\n[유동부채]\n59,687,458,641\xa0\n47,855,143,190\xa0\n54,516,684,923\n[비유동부채]\n18,622,450,959\xa0\n14,658,459,606\xa0\n16,678,553,018\n부채총계\n78,309,909,600\xa0\n62,513,602,796\xa0\n71,195,237,941\n[자본금]\n21,159,832,000\xa0\n20,195,149,000\xa0\n19,276,090,000\n[주식발행초과금]\n1,112,256,192\xa0\n2,076,939,192\xa0\n2,995,998,192\n[기타포괄손익누계액]\n50,387,669,798\xa0\n29,768,646,556\xa0\n29,430,639,780\n[기타자본항목]\n15,675,311,051\xa0\n15,706,379,971\xa0\n15,770,814,508\n[이익잉여금]\n(3,390,981,806)\n6,326,958,321\xa0\n1,094,519,493\n지배기업소유주지분\n84,944,087,235\xa0\n74,074,073,040\xa0\n68,568,061,973\n비지배지분\n5,486,372\xa0\n5,186,970\xa0\n19,746,770\n자본총계\n84,949,573,607\xa0\n74,079,260,010\xa0\n68,587,808,743\n부채와자본총계\n163,259,483,207\xa0\n136,592,862,806\xa0\n139,783,046,684\n매출액\n135,372,690,530\xa0\n126,583,402,933\xa0\n119,745,568,736\n영업이익(손실)\n(1,989,142,940)\n5,272,527,164\xa0\n(1,675,903,581)\n당기순이익(손실)\n(8,414,888,054)\n3,542,773,665\xa0\n(1,555,791,280)\n\xa01.지배기업소유주지분\n(8,415,187,456)\n3,557,333,465\xa0\n(1,559,131,377)\n\xa02.비지배지분\n299,402\xa0\n(14,559,800)\n3,340,097\n기타포괄손익\n19,316,270,571\xa0\n2,012,502,512\xa0\n(309,724,959)\n당기총포괄손익\n10,901,382,517\xa0\n5,555,276,177\xa0\n(1,865,516,239)\n\xa01.지배기업소유주지분\n10,901,083,115\xa0\n5,569,835,977\xa0\n(1,868,856,336)\n\xa02.비지배지분\n299,402\xa0\n(14,559,800)\n3,340,097\n주당순이익(손실)\n(415)\n176\xa0\n(81)\n연결에 포함된 회사수\n1\xa0\n1\xa0\n1\n<종속기업 재무정보 요약>\n(2023년)\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,866,694\n102,869\n4,098,517\n5,614\n(2022년) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,549,447\n97,256\n2,992,330\n(272,996)\n(2021년) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,661,479\n370,252\n4,018,304\n62,627\n요약재무정보\n국제약품(주) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n(단위 : 원)\n구 분\n제66기\n제65기\n제64기\n[유동자산]\n54,144,098,428\xa0\n47,872,340,430\xa0\n47,509,136,962\xa0\n-현금및현금성자산\n10,347,242,029\xa0\n5,309,615,691\xa0\n7,654,384,083\xa0\n-매출채권\n20,036,732,288\xa0\n18,850,395,307\xa0\n20,228,765,209\xa0\n-재고자산\n21,053,004,376\xa0\n22,078,821,355\xa0\n16,491,918,820\xa0\n-기타유동자산\n2,707,119,735\xa0\n1,633,508,077\xa0\n3,134,068,850\xa0\n[비유동자산]\n107,427,998,887\xa0\n87,116,481,391\xa0\n90,628,761,663\xa0\n-유형자산\n98,377,282,722\xa0\n76,668,342,346\xa0\n79,572,383,576\xa0\n-무형자산\n885,293,500\xa0\n1,077,738,761\xa0\n1,271,874,285\xa0\n-투자부동산\n3,157,023,994\xa0\n3,314,752,009\xa0\n3,453,461,341\xa0\n-기타비유동자산\n5,008,398,671\xa0\n6,055,648,275\xa0\n6,331,042,461\xa0\n자산총계\n161,572,097,315\xa0\n134,988,821,821\xa0\n138,137,898,625\xa0\n[유동부채]\n59,338,341,983\xa0\n47,637,353,361\xa0\n54,321,860,051\xa0\n[비유동부채]\n18,557,561,726\xa0\n14,539,844,444\xa0\n16,314,880,710\xa0\n부채총계\n77,895,903,709\xa0\n62,177,197,805\xa0\n70,636,740,761\xa0\n[자본금]\n21,159,832,000\xa0\n20,195,149,000\xa0\n19,276,090,000\xa0\n[주식발행초과금]\n1,112,256,192\xa0\n2,076,939,192\xa0\n2,995,998,192\xa0\n[기타포괄손익누계액]\n50,287,530,951\xa0\n29,668,637,929\xa0\n29,308,727,106\xa0\n[기타자본항목]\n15,848,654,978\xa0\n15,879,723,898\xa0\n15,944,158,435\xa0\n[이익잉여금]\n(4,732,080,515)\n4,991,173,997\xa0\n(23,815,869)\n자본총계\n83,676,193,606\xa0\n72,811,624,016\xa0\n67,501,157,864\xa0\n자본과부채총계\n161,572,097,315\xa0\n134,988,821,821\xa0\n138,137,898,625\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n131,274,173,963\xa0\n123,598,850,791\xa0\n115,744,739,600\xa0\n영업이익(손실)\n(2,042,839,652)\n5,542,738,674\xa0\n(1,747,037,562)\n당기순이익(손실)\n(8,420,501,841)\n3,339,884,503\xa0\n(1,548,270,487)\n기타포괄손익\n19,316,140,351\xa0\n2,011,200,317\xa0\n(332,931,201)\n당기총포괄손익\n10,895,638,510\xa0\n5,351,084,820\xa0\n(1,881,201,688)\n주당순이익(손실)\n(416)\n165\xa0\n(80)\n']"
